Home / Publication / A Sequential Population Pharmacokinetic Model of Zilovertamab Vedotin in Patients with Hematologic Malignancies Extrapolated to the Pediatric Population

論文

A Sequential Population Pharmacokinetic Model of Zilovertamab Vedotin in Patients with Hematologic Malignancies Extrapolated to the Pediatric Population

Author(s): Thijs J. Zweers, Jos Lommerse, Eline van Maanen, Manash S. Chatterjee

Year: 2024年10月22日

Adaptive clinical trials in oncology: Meeting the challenge of Project Optimus

ブログ

CHI ADC Webinar: Start Right-Finish Strong: Antibody-Drug Conjugate (ADC) Studies For Success

ウェビナー

Regulatory Horizons: Strategic Global Insights & 2026 Outlook from Former Leaders of Major Regulatory Agencies

ウェビナー

Safety First: Uncovering the Clinical Risks Inside Your Compound Screening Data

ウェビナー

Powered by Translations.com GlobalLink Web Software

A Sequential Population Pharmacokinetic Model of Zilovertamab Vedotin in Patients with Hematologic Malignancies Extrapolated to the Pediatric Population

A Sequential Population Pharmacokinetic Model of Zilovertamab Vedotin in Patients with Hematologic Malignancies Extrapolated to the Pediatric Population

Adaptive clinical trials in oncology: Meeting the challenge of Project Optimus

CHI ADC Webinar: Start Right-Finish Strong: Antibody-Drug Conjugate (ADC) Studies For Success

Regulatory Horizons: Strategic Global Insights & 2026 Outlook from Former Leaders of Major Regulatory Agencies

Safety First: Uncovering the Clinical Risks Inside Your Compound Screening Data

メルマガ登録

クイックアクセス

ソリューション

お問合せ